SEOM guidelines for the management of Malignant Melanoma 2015
-
A. Berrocal [2] ; A. Arance [9] ; E. Espinosa [3] ; A. G. Castaño [4] ; M. G. Cao [10] ; J. L. G. Larriba [5] ; J. A. L. Martín [6] ; I. Márquez [7] ; A. Soria [8] ; S. M. Algarra [1]
-
[1] Clínica Universitaria de Navarra
Clínica Universitaria de Navarra
Pamplona, España
-
[2] Hospital General Universitario de Valencia
Hospital General Universitario de Valencia
Valencia, España
-
[3] Hospital Universitario La Paz
Hospital Universitario La Paz
Madrid, España
-
[4] Hospital Universitario Marqués de Valdecilla
Hospital Universitario Marqués de Valdecilla
Santander, España
-
[5] Hospital Clínico San Carlos de Madrid
Hospital Clínico San Carlos de Madrid
Madrid, España
-
[6] Hospital Universitario 12 de Octubre
Hospital Universitario 12 de Octubre
Madrid, España
-
[7] Hospital General Universitario Gregorio Marañón
Hospital General Universitario Gregorio Marañón
Madrid, España
-
[8] Hospital Ramón y Cajal
Hospital Ramón y Cajal
Madrid, España
-
[9] Hospital Clinic
-
[10] Hospital Universitario Quirón Dexeus
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 17, Nº. 12, 2015, págs. 1030-1035
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
All melanoma patients must be confirmed histologically and resected according to Breslow. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon must be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 therapy. Up to 10 years follow up is recommended for melanoma patients with dermatologic examinations and physical exams.
